Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Rua Life Sciences PLC

Healthcare GB RUA

19.5GBX
-0.5(2.50%)

Last update at 2026-06-05T15:10:00Z

Day Range

19.2519.90
LowHigh

52 Week Range

10.4216.80
LowHigh

Fundamentals

  • Previous Close 20.00
  • Market Cap8.07M
  • Volume79149
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA0.27M
  • Revenue TTM4.46M
  • Revenue Per Share TTM0.07
  • Gross Profit TTM 3.46M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax -0.15733M -0.01000M -2.02000M -2.32200M -2.36000M
Minority interest - - 0.00000M - -
Net income -0.14533M 0.00100M -1.44000M -2.00300M -2.06700M
Selling general administrative - 4.16M 1.15M 4.17M 3.31M
Selling and marketing expenses - - 0.01M 0.02M 0.00900M
Gross profit 3.06M 3.17M 1.72M 1.79M 1.36M
Reconciled depreciation - - 0.36M 0.36M 0.31M
Ebit -0.82667M -0.02000M -1.93700M -2.30600M -2.34800M
Ebitda -0.38333M 0.40M -1.57300M -1.94800M -2.03600M
Depreciation and amortization 0.44M 0.42M 0.36M 0.36M 0.31M
Non operating income net other - - - - -
Operating income -0.82667M -0.98900M -1.93700M -2.30600M -2.35200M
Other operating expenses 5.29M 4.13M 4.13M 4.49M 3.97M
Interest expense - - 0.08M 0.02M 0.00800M
Tax provision - - -0.58000M -0.31900M -0.29300M
Interest income - - - - -
Net interest income - - -0.08300M -0.01600M -0.00800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.00200M 0.01M -0.58000M -0.31900M -0.29300M
Total revenue 4.46M 4.11M 2.19M 2.18M 1.62M
Total operating expenses 3.88M 3.19M 3.40M 4.10M 3.71M
Cost of revenue 1.40M 0.94M 0.47M 0.39M 0.27M
Total other income expense net 0.67M 0.98M -0.08300M -0.01600M -0.00800M
Discontinued operations - - - - -
Net income from continuing ops - - -1.44000M -2.00300M -2.06700M
Net income applicable to common shares - - - - -2.06700M
Preferred stock and other adjustments - - - - -
Breakdown 2025-09-30 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 9.12M 9.26M 8.17M 5.66M 7.63M
Intangible assets 0.35M 0.38M 0.42M 0.47M 0.52M
Earning assets - - - - -
Other current assets - - 0.42M 1.12M 1.12M
Total liab 1.89M 1.86M 0.99M 0.98M 1.04M
Total stockholder equity 7.14M 7.30M 7.18M 4.68M 6.58M
Deferred long term liab - - - - -
Other current liab 0.76M 0.03M 0.30M 0.05M 0.04M
Common stock 3.10M 3.10M 3.10M 1.11M 1.11M
Capital stock - - 3.10M 1.11M 1.11M
Retained earnings -20.20300M -19.97900M -19.98500M -18.54500M -16.54200M
Other liab - - - - 0.25M
Good will 0.30M 0.30M 0.30M 0.30M 0.30M
Other assets - - - - -
Cash 3.25M 3.57M 3.93M 1.48M 2.96M
Cash and equivalents - - - - -
Total current liabilities 1.16M 1.10M 0.55M 0.41M 0.51M
Current deferred revenue - - -0.22200M - -
Net debt -2.45600M -2.53800M -3.54200M -1.00900M -2.61900M
Short term debt 0.23M 0.39M 0.12M 0.11M 0.06M
Short long term debt - - 0.03M 0.03M 0.02M
Short long term debt total 0.79M 1.03M 0.39M 0.47M 0.34M
Other stockholder equity 13.71M 13.71M 13.71M 17.44M 15.43M
Property plant equipment - - - - 2.60M
Total current assets 5.39M 5.41M 4.99M 2.15M 4.21M
Long term investments - - - - -
Net tangible assets - - - - 5.76M
Short term investments - - - - -
Net receivables 1.25M 1.09M 0.53M 0.59M 1.12M
Long term debt - - 0.13M 0.17M 0.20M
Inventory 0.89M 0.75M 0.11M 0.08M 0.12M
Accounts payable 0.17M 0.68M 0.14M 0.26M 0.41M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 10.54M 10.46M 10.36M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - -3.51000M -3.41900M
Deferred long term asset charges - - - - -
Non current assets total 3.72M 3.84M 3.18M 3.51M 3.42M
Capital lease obligations - - 0.23M 0.28M 0.12M
Long term debt total - - - - -
Breakdown 2025-09-30 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments - - -0.08500M -0.47700M -0.91200M
Change to liabilities - - - - -0.45300M
Total cashflows from investing activities -0.05900M 0.07M -0.08500M - -0.91200M
Net borrowings - - -0.08600M - -0.06600M
Total cash from financing activities -0.45900M -0.19600M 3.89M 0.13M -0.06600M
Change to operating activities - - - - -
Net income -0.14533M 0.00100M -1.44000M -2.00300M -2.06700M
Change in cash -0.68100M -0.36400M 2.45M -1.47900M -3.33100M
Begin period cash flow 3.93M 3.93M 1.48M 2.96M 6.29M
End period cash flow 3.25M 3.57M 3.93M 1.48M 2.96M
Total cash from operating activities -0.13700M -0.21900M -1.32800M -1.14600M -2.35300M
Issuance of capital stock - - 3.97M - 0.00000M
Depreciation 0.44M 0.42M 0.36M 0.36M 0.31M
Other cashflows from investing activities - 0.03M -0.03000M - -0.00800M
Dividends paid - - - - -
Change to inventory -0.20600M 0.00200M -0.03100M 0.04M -0.03900M
Change to account receivables 0.15M 0.18M -0.36200M 0.33M -0.05300M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - -0.08500M 0.23M -0.91200M
Change to netincome - - - - -0.14000M
Capital expenditures 0.16M 0.06M 0.06M 0.45M 0.90M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.12M 0.18M -0.28900M 0.17M -0.54500M
Stock based compensation - 0.11M -0.03500M 0.10M 0.14M
Other non cash items -0.55800M -0.93300M 0.07M 0.02M 0.00800M
Free cash flow -0.29800M -0.28100M -1.38300M -1.59500M -3.25700M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RUA
Rua Life Sciences PLC		 -0.5 2.50% 19.50 - 16.89 1.81 1.11 1.33 13.61
SN
Smith & Nephew PLC		 14.50 1.28% 1147.00 23.24 12.47 1.70 2.59 2.67 10.76
NIOX
NIOX Group PLC		 -1.2 1.96% 60.00 28.20 18.73 4.84 3.41 4.35 13.85
EKF
EKF Diagnostics Holdings Plc		 -0.2 0.75% 26.40 - 34.97 2.02 1.46 1.72 7.01
CREO
Creo Medical Group PLC		 - -% 13.75 - - 199.36 0.74 6.21 8.16

Reports Covered

Stock Research & News

View All

Profile

RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart. The company acts as the depository of intellectual property and licensing rights to various biostable and implantable polymers, including Elast-Eon and ECSil; and provides sub-contract manufacturing, assembly, packing, and services of medical device, as well as implantable fabric. It also engages in the development and commercialization of bore polymer sealed grafts and soft tissue patches; and development of tri-leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.

Rua Life Sciences PLC

2 Drummond Crescent, Irvine, United Kingdom, KA11 5AN

Key Executives

Name Title Year Born
Mr. William Donald Brown Exec. Chairman 1964
Mr. John McKenna Director of Clinical Marketing & Exec. Director 1953
Dr. Caroline Stretton Group MD & Director 1971
Mr. Lachlan Smith CFO & Director NA
Mr. Iain Anthony Director of Clinical & Regulatory Affairs and Director NA
K. M. Full FCCA Company Sec. NA
Mr. William Donald Brown Chief Executive Officer & Director 1963
Mr. Lachlan Arthur Smith CFO, Company Secretary & Director 1980

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions